SCHEMBL64911

SCHEMBL64911

NC1=NC2(N)N=CN=C2C=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712126 0.74
SCHEMBL7718436 0.64
SCHEMBL3685876 0.56
SCHEMBL2374044 0.53
SCHEMBL9774599 0.52
SCHEMBL2885121 0.52
SCHEMBL7530927 0.51
SCHEMBL33790 0.49
SCHEMBL31299889 0.48
SCHEMBL22193800 0.47

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 870 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2179039-B1 RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES ZOETIS BELGIUM S A (BE) 2018-10-31 EP claimed
EP-2451475-A2 SELF REPLICATING RNA MOLECULES AND USES THEREOF Novartis AG (CH) 2012-05-16 EP claimed
US-8128944-B2 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles COLEY PHARMACEUTICAL GMBH (DE) 2012-03-06 US claimed
US-20110300205-A1 SELF REPLICATING RNA MOLECULES AND USES THEREOF NOVARTIS AG (CH) 2011-12-08 US claimed
WO-2011005799-A2 SELF REPLICATING RNA MOLECULES AND USES THEREOF NOVARTIS AG (CH) 2011-01-13 WO claimed
US-20100272785-A1 RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES COLEY PHARMACEUTICAL GMBH (DE) 2010-10-28 US claimed
EP-2179039-A2 RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES Coley Pharmaceuticals GmbH (DE) 2010-04-28 EP claimed
WO-2009022216-A9 RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES COLEY PHARM GMBH (DE) 2009-04-30 WO claimed
WO-2009022216-A2 RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES COLEY PHARMACEUTICAL GMBH (US) 2009-02-19 WO claimed
WO-2008033432-A2 IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-03-20 WO claimed
US-20060241076-A1 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity COLEY PHARMACEUTICAL GMBH (DE) 2006-10-26 US claimed
JP-2002523335-A 2002-07-30 JP claimed
US-6388061-B1 INCLUDES RUTHENIUM TRIS(BIPYRIDYL) LABEL BONDED TO THE NITROGEN BASE DAKO A/S (DK) 2002-05-14 US claimed
US-20010021772-A1 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-09-13 US claimed
EP-1102842-A2 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION Aventis Pharma Deutschland GmbH (DE) 2001-05-30 EP claimed
EP-1100894-A2 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION Aventis Pharma Deutschland GmbH (DE) 2001-05-23 EP claimed
WO-2000008141-A2 SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-02-17 WO claimed
WO-2000008140-A2 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-02-17 WO claimed
EP-0979869-A1 Short oligonucleotides for the inhibition of VEGF expression Hoechst Marion Roussel Deutschland GmbH (DE) 2000-02-16 EP claimed
EP-0978561-A1 Antisense oligonucleotides for the inhibition of VEGF expression Hoechst Marion Roussel Deutschland GmbH (DE) 2000-02-09 EP claimed